Illumina Hi-Seq 2000 Sequencing System

描述（由申请人提供）：新一代超高通量DNA测序仪正在改变生物医学研究。这些仪器为基础和临床研究提供了广泛的应用，包括SNP发现，转录组谱分析，蛋白质：DNA相互作用和超敏位点的鉴定以及表征 全基因组规模上的甲基化和染色质标记。该提案寻求资金，通过增加Illumina公司生产的HiSeq 2000系统下一代DNA测序仪，扩大杜克大学基因组测序与分析核心设施内的仪器。核心设施内现有的下一代能力包括四个短读仪器（三个Illumina GAII”和一个Applied Biosystems SOLiD”4“）和一个长读仪器（Roche GS-FLX”）。我们在三年前获得了第一台GAII”，用新的HiSeq”2000取代这台仪器将大大扩大容量，以满足不断增长的需求，并扩大核心设施为研究人员提供的服务范围。HiSeq平台提供了更大的吞吐量和更快的运行时间。使用该工具将 从而节省了一些研究项目的时间和成本，并为其他项目提供了扩展信息。该工具将主要由八名确定的杜克研究人员用于正在进行的项目的多样性。由于Illumina在核心设施中已有强大的用户基础和HiSeq的多功能性，我们预计这种新仪器将在其生命周期内实现广泛的额外项目。该仪器的有效利用是通过放置在一个核心设施中来确保的，该设施具有十多年支持研究项目的成就记录。由于这种新仪器将取代旧的Illumina仪器，因此可以很容易地将其集成到既定的工作流程中，并且不需要额外的辅助设备，工作人员和计算基础设施。核心设施提供与研究人员的从头到尾的合作伙伴关系，包括咨询，样品制备，文库构建，DNA测序，运行后质量控制以及深入的生物信息学和统计分析。一组在操作各种下一代DNA测序仪方面具有丰富经验的技术人员和生物信息学家将为新仪器提供支持，使非专业人员能够立即利用其能力。HiSeq 2000 DNA测序仪将为NIH资助的几个正在进行的项目提供实质性的好处，并作为杜克大学充满活力的生物医学研究社区的其他项目的宝贵催化剂。

DESCRIPTION (provided by applicant): A new generation of ultra high-throughput DNA sequencers is transforming biomedical research. These instruments provide a wide range of applications to basic and clinical research, including SNP discovery, analysis of transcriptome profiles, identification of protein:DNA interactions and hypersensitive sites, and characterization of methylation and chromatin marks at the whole-genome scale. This proposal seeks funds to expand instrumentation within Duke University's Genome Sequencing & Analysis Core Facility by adding a HiSeq" 2000 System next-generation DNA sequencer manufactured by Illumina. Existing next-generation capabilities within the Core Facility include four short-read instruments (three Illumina GAII" and one Applied Biosystems SOLiD" 4) and one long-read instrument (Roche GS-FLX"). We acquired our first GAII" three years ago and replacing this instrument with the new HiSeq" 2000 would substantially expand capacity to meet growing demand and extend the range of services that the Core Facility provides to researchers. The HiSeq" platform offers both a substantially larger throughput and a faster run time. Access to this instrument will therefore save some research projects time and cost, and provide others with expanded information. This instrument will be primarily utilized by eight identified Duke investigators for diversity of ongoing projects. Because of a pre-existing strong Illumina user base in the Core Facility and the HiSeq" versatility, we anticipate that this new instrument will enable a wide range of additional projects over its lifetime. Efficient utilization of the instrument is ensured y placement in a Core Facility with a proven record of accomplishment of more than a decade of support for research projects. Since this new instrument would replace an older Illumina instrument, its integration to an established workflow would be easily achieved and no additional ancillary equipment, staff, and computing infrastructure would be required. The Core Facility provides start-to- finish partnership with investigators that includes consultation, sample preparation, library construction, DNA sequencing, post-run quality control, and in-depth bioinformatics and statistical analyses. A team of technicians and bioinformaticians with strong experience in operating various next-generation DNA sequencers would support the new instrument, allowing non-specialists to take immediate advantage of its capabilities. A HiSeq" 2000 DNA sequencer would provide substantial benefit to several ongoing NIH-funded projects and serve as a valuable catalyst for additional projects throughout Duke University's vibrant biomedical research community.